Literature DB >> 32871473

Sirolimus versus cyclosporine for the treatment of pediatric chronic immune thrombocytopenia: A randomized blinded trial.

Morteza Mousavi-Hasanzadeh1, Bahador Bagheri2, Sarvenaz Mehrabi1, Aygin Eghbali3, Aziz Eghbali4.   

Abstract

INTRODUCTION: Chronic immune thrombocytopenia (ITP) of childhood is still a problem. For treating ITP, several immunosuppressive medications can be considered with various response rates. Our goal was to compare effects of sirolimus and cyclosporine on children with chronic ITP.
METHODS: This randomized and blinded trial was carried out on 67 children over 5 years old with chronic ITP. Patients were assigned 1:1 to cyclosporine and sirolimus for 6 months. Platelet count was assessed and compared between 2 study groups at different intervals. The clinical trial registry number was IRCT20180501039499N1.
RESULTS: Sixty-one children completed the 6-month treatment. Mean age was 9.3 years with an excess of females. Compared to baseline values, both drugs caused a significant increase in number of platelets over the course of treatment; sirolimus group: 15,800/mcL vs 96,566/mcL, (P < 0.001), cyclosporine group: 14,400/mcL vs 111,266/mcL, P < 0.001,). In addition, differences of platelet number were statistically significant at some treatment intervals (3rd and 6th month, P < 0.05). A quicker response was observed in children receiving cyclosporine. Both drugs had similar rate of response which occurred in 50% of included patients. Finally, sirolimus had a better safety profile.
CONCLUSIONS: Our study showed that cyclosporine and sirolimus had an equal rate of response in treating chronic ITP of children. At the same time, the two medications showed significant differences in their side effects.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chronic; Cyclosporine; ITP; Platelets; Sirolimous

Mesh:

Substances:

Year:  2020        PMID: 32871473     DOI: 10.1016/j.intimp.2020.106895

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  6 in total

1.  Efficacy and safety of cyclosporine A treatment in autoimmune cytopenias: the experience of two Italian reference centers.

Authors:  Bruno Fattizzo; Silvia Cantoni; Juri Alessandro Giannotta; Laura Bandiera; Rachele Zavaglia; Marta Bortolotti; Wilma Barcellini
Journal:  Ther Adv Hematol       Date:  2022-05-14

2.  Use of bioinformatic analyses in identifying characteristic genes and mechanisms active in the progression of idiopathic thrombocytopenic purpura in individuals with different phenotypes.

Authors:  Mengyi Zhang; Binhan Guo
Journal:  J Int Med Res       Date:  2020-11       Impact factor: 1.671

3.  Case Report: Sirolimus Alleviates Persistent Cytopenia After CD19 CAR-T-Cell Therapy.

Authors:  Limin Xing; Yihao Wang; Hui Liu; Shan Gao; Qing Shao; Lanzhu Yue; Zhaoyun Liu; Huaquan Wang; Zonghong Shao; Rong Fu
Journal:  Front Oncol       Date:  2021-12-23       Impact factor: 6.244

4.  Sirolimus Monotherapy for Thrombocytopenia in Primary Antiphospholipid Syndrome: A Pilot Study From a Tertiary Referral Center.

Authors:  Wenhui Xie; Lanlan Ji; Zhuoli Zhang
Journal:  Front Immunol       Date:  2022-03-25       Impact factor: 7.561

5.  Initial sirolimus dosage recommendations for pediatric patients with PIK3CD mutation-related immunodeficiency disease.

Authors:  Xiao Chen; Jinglin Wang; Jianger Lan; Xilin Ge; Hong Xu; Yu Zhang; Zhiping Li
Journal:  Front Pharmacol       Date:  2022-09-14       Impact factor: 5.988

6.  Immunological characteristics and effect of cyclosporin in patients with immune thrombocytopenia.

Authors:  Ting Wang; Xin He; Ningyuan Ran; Chunyan Liu; Limin Xing; Huaquan Wang; Rong Fu; Zonghong Shao
Journal:  J Clin Lab Anal       Date:  2021-07-30       Impact factor: 2.352

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.